FDG-PET in monitoring therapy of breast cancer

被引：30

作者：

Biersack, HJ ^{[1
]}

Bender, H ^{[1
]}

Palmedo, H ^{[1
]}

机构：

[1] Univ Hosp Bonn, Dept Nucl Med, D-53127 Bonn, Germany

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2004年 / 31卷 / Suppl 1期

关键词：

breast cancer; FDG-PET; treatment response; chemotherapy; radiation therapy;

D O I：

10.1007/s00259-004-1533-x

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been used successfully for the staging and re-staging of breast cancer. Another significant indication is the evaluation of therapy response. Only limited data are available on the use of FDG-PET in breast cancer after radiation therapy. The same holds true for chemotherapy. Only the therapy response in locally advanced breast cancer after chemotherapy has been investigated thoroughly. Histopathological response could be predicted with an accuracy of 88-91% after the first and second courses of therapy. A quantitative evaluation is, of course, a prerequisite when FDG-PET is used for therapy monitoring. Only a small number of studies have focussed on hormone therapy. In this context, a flare phenomenon with increasing standardised uptake values after initiation of tamoxifen therapy has been observed. More prospective multicentre trials will be needed to make FDG-PET a powerful tool in monitoring chemotherapy in breast cancer.

引用

页码：S112 / S117

页数：6

共 36 条

[1]

Bassa P, 1996, J NUCL MED, V37, P931

[2] Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer [J].

Bender, H ;

Bangard, N ;

Metten, N ;

Bangard, M ;

Mezger, J ;

Schomburg, A ;

Biersack, HJ .

HYBRIDOMA, 1999, 18 (01) :87-91

[3]

Biersack HJ, 2001, NUCL MED A, P69

[4]

Biersack HJ, 2003, J NUCL MED, V44, P1815

[5]

Bockisch A, 2004, PET AND PET-CT IN ONCOLOGY, P101

[6]

BOOSER DJ, 1992, SEMIN ONCOL, V19, P278

[7] Clinical and pathological response to primary chemotherapy in operable breast cancer [J].

Chollet, P ;

Charrier, S ;

Brain, E ;

Cure, H ;

vanPraagh, I ;

Feillel, V ;

deLatour, M ;

Dauplat, J ;

Misset, JL ;

Ferriere, JP .

EUROPEAN JOURNAL OF CANCER, 1997, 33 (06) :862-866

[8] Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy [J].

Dehdashti, F ;

Flanagan, FL ;

Mortimer, JE ;

Katzenellenbogen, JA ;

Welch, MJ ;

Siegel, BA .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (01) :51-56

[9] Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 [J].

Fisher, B ;

Brown, A ;

Mamounas, E ;

Wieand, S ;

Robidoux, A ;

Margolese, RG ;

Cruz, AB ;

Fisher, ER ;

Wickerham, DL ;

Wolmark, N ;

DeCillis, A ;

Hoehn, JL ;

Lees, AW ;

Dimitrov, NV .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) :2483-2493

[10]

Gennari A, 2000, Clin Breast Cancer, V1, P156, DOI 10.3816/CBC.2000.n.014

← 1 2 3 4 →